SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| VIPDOMET 12.5 mg/1000 mg TABLETS | 1000,12.5 mg,mg | Film-coated tablet · Oral use | 56 Blister | SAR 117.45 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| VIPDOMET 12.5 mg/500 mg TABLETS | 500,12.5 mg,mg | Film-coated tablet · Oral use | 56 Blister | SAR 109.90 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZYTERO PLUS 12.5 mg/ 1000 mg Film Coated Tablet | 1000,12.5 mg,mg | Film-coated tablet · Oral use | 56 Blister | SAR 117.45 | NCE · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| ZYTERO PLUS 12.5 mg/ 500 mg Film Coated Tablet | 500,12.5 mg,mg | Film-coated tablet · Oral use | 56 Blister | SAR 109.90 | NCE · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| VIPDOMET 12.5 mg/1000 mg TABLETS | 12.5, 1000 mg | Film-coated tablet · Oral use | 56 Blister | SAR 117.45 | NCE · Prescription | TAKEDA PHARMACEUTICALS USA, INC. | Withdrawn by MAH · Not Marketed |
| VIPDOMET 12.5 mg/500 mg TABLETS | 12.5, 1000 mg | Film-coated tablet · Oral use | 56 Blister | SAR 109.90 | NCE · Prescription | TAKEDA PHARMACEUTICALS USA, INC. | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
DIABETES MELLITUS TYPE 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| KAZANO | EQ 12.5MG BASE;500MG; EQ 12.5MG BASE;1GM | tablet · oral | TAKEDA PHARMS USA | Prescription | 25 Jan 2013 |
EMA European Union — centrally authorised medicines
Vipdomet Takeda Pharma A/S · Authorised · authorised 18 Sep 2013 · ATC A10BD13
Therapeutic indication (EMA)
Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin; in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone; in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| KAZANO | 02417219 | 500 MG; 12.5 MG | TABLET · ORAL | TAKEDA CANADA INC |
| KAZANO | 02417227 | 850 MG; 12.5 MG | TABLET · ORAL | TAKEDA CANADA INC |
| KAZANO | 02417235 | 12.5 MG; 1000 MG | TABLET · ORAL | TAKEDA CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | ALOGLIPTIN-METFORMIN 12.5-1000 | $2.46491 | per EA | 23 Sep 2026 |
| US NADAC | ALOGLIPTIN-METFORMIN 12.5-500 | $2.3206 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Alogliptin 12.5mg / Metformin 1g tablets | £26.60 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.